Authors

Latest:

Dr Llombart-Cussac on the Implications of Prophylaxis for Neutropenia and Diarrhea in Advanced Breast Cancer

Antonio Llombart-Cussac, MD, PhD, on the implications of prophylaxis for sacituzumab govitecan–related neutropenia and diarrhea in advanced breast cancer.

Antonio Palumbo, MD

Latest:

Dr. Palumbo on Significance of Daratumumab Triplet in Multiple Myeloma

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the impact the triplet regimen of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone will have on the field of multiple myeloma.

Antonio Passaro, MD, PhD

Latest:

Dr Passaro on the Role of MET in Guiding Treatment Strategies After EGFR TKI Progression in NSCLC

Antonio Passaro, MD, PhD, discusses testing methodologies and clinical trials for MET, the most studied resistance biomarker, following progression on EGFR TKIs.

Anuradha S. Budhu, PhD

Latest:

Potential Molecular Markers in Liver Cancer

Anuradha S. Budhu, PhD, discusses using molecular features as predictive markers in liver cancer.

Apar Kishor Ganti, MD

Apar Kishor Ganti, MD, is a professor in the University of Nebraska Medical Center Division of Oncology & Hematology, the Dr. and Mrs. D. Leon UMNC Research Fund Chair in Internal Medicine, and the associate director for Clinical Research at the Fred & Pamela Buffett Cancer Center

Latest:

FDA Approval Insights: Oncomine DX Express Test Companion Diagnostic for Sunvozertinib in Non–Small Cell Lung Cancer: With Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP

Drs Ganti and Cushman discuss the launch of the Oncomine DX Express Test, as well as the benefits and limitations of rapid next-generation sequencing.

Aparna R. Parikh, MD

Latest:

Dr Parikh on the Clinical Implications of Molecular Testing on mCRC Management

Aparna Parikh, MD, discusses the importance of upfront molecular testing in patients with metastatic colorectal cancer.

Apostolia M. Tsimberidou, MD, PhD

Latest:

Dr. Tsimberidou on the Impact Trial in Patients With Advanced Cancer

Apostolia Maria Tsimberidou, MD, PhD, tenured professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, discusses the IMPACT trial in patients with advanced cancer.

Apostolia Tsimberidou, MD, PhD

Latest:

Dr. Tsimberidou on the Next Steps for Personalized Care

Dr. Apostolia Tsimberidou from MD Anderson Cancer Center on the Next Steps for Personalized Care

Aradhana Kaushal, MD

Latest:

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Arantxa Romero-Toledo, PhD

Latest:

Impact of BTK Inhibition on Monocytic Myeloid-Derived Suppressor Cells in CLL

Arantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).

Areej R. El-Jawahri, MD

Latest:

Dr El-Jawahri on the Benefits of Earlier Palliative Care in Hematologic Malignancies

Areej El-Jawahri, MD, discusses the potential benefits of earlier palliative care for patients with hematologic malignancies.

Aref Al-Kali, MD

Latest:

Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALL

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

Ari M. Melnick, MD

Latest:

Dr. Melnick on Targeting EZH2 in DLBCL

Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B-cell lymphoma.

Ari VanderWalde, MD

Latest:

Dr. VanderWalde on the Clinical Implications of IMpower150 and KEYNOTE-021

Ari VanderWalde, MD, MPH, director, West Cancer Center, assistant professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, discusses the design of the IMpower150 and KEYNOTE-021 trials.

Ari Zimran, MD

Latest:

Dr. Zimran Discusses Gaucher Disease Biomarkers

Dr. Ari Zimran, from Shaare Zedek Medical Center, Jerusalem, Discusses Biomarkers in Gaucher Disease

Arie Dosoretz MD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Arie P. Dosoretz, MD

Latest:

Changes in Prostate Cancer Presentation for Radiation Oncology Care

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Arie Perry, MD

Latest:

Dr. Perry on Implications of WHO Tumor Classifications in Brain Cancer

Arie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.

Ariel E. Marciscano, MD

Latest:

Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis

Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.

Ariela Katz

Latest:

An Explorer's Mentality Leads to Novel Treatments in Prostate and Bladder Cancer

Although he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.